Post-translational modification (PTM) of antigens provides an additional source of
specificities targeted by immune responses to tumors or pathogens, but identifying antigen …

Efforts to precisely identify tumor human leukocyte antigen (HLA) bound peptides capable of
mediating T cell-based tumor rejection still face important challenges. Recent studies …

MHC-I-associated peptides deriving from non-coding genomic regions and mutations can
generate tumor-specific antigens, including neoantigens. Quantifying tumor-specific …

Antigen recognition by CD8+ T cells is governed by the pool of peptide antigens presented
on the cell surface in the context of HLA class I complexes. Studies have shown not only a …

Immunosurveillance of cancer requires the presentation of peptide antigens on major
histocompatibility complex class I (MHC-I) molecules,,,–. Current approaches to profiling of …

The identification of actionable tumor antigens is indispensable for the development of
several cancer immunotherapies, including T cell receptor–transduced T cells and patient …

T cell receptor (TCR)–based immunotherapy has emerged as a promising therapeutic
approach for the treatment of patients with solid cancers. Identifying peptide–human …

Anticancer immunotherapies demand optimal epitope targets, which could include
proteasome-generated spliced peptides if tumor cells were to present them. Here, we show …

The antigenicity of cells is demarcated by the peptides bound by their Human Leucocyte
Antigen (HLA) molecules. Through this antigen presentation, T cell specificity response is …

Recent data indicate that endogenous mutated cancer proteins can be processed and
presented as HLA binding peptides, leading to their recognition in vivo as “non-self.” …